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doi:10.1Objective: Adenosine A2A receptor activation after lung transplantation attenuates ischemia–reperfusion injury
by reducing inflammation. However, the effect of adenosine A2A receptor activation in donor lungs before trans-
plant remains ill defined. This study compares the efficacy of 3 different treatment strategies for adenosine A2A
receptor agonist in a clinically relevant porcine lung transplantation model.
Methods: Mature porcine lungs underwent 6 hours of cold ischemia before allotransplantation and 4 hours of
reperfusion. Five groups (n ¼ 6/group) were evaluated on the basis of treatment with ATL-1223, a selective
adenosine A2A receptor agonist: thoracotomy alone (sham), transplant alone (ischemia–reperfusion), donor pre-
treatment via ATL-1223 bolus (ATL-D), recipient treatment via ATL-1223 infusion (ATL-R), and a combination
of both ATL-1223 treatments (ATL-D/R). Lung function and injury were compared.
Results:Blood oxygenation was significantly higher among ATL-D, ATL-R, and ATL-D/R groups versus ische-
mia–reperfusion (392.0 52.5, 428.9 25.5, and 509.4 25.1 vs 77.2 17.0 mm Hg, respectively, P<.001).
ATL-1223–treated groups had lower pulmonary artery pressures (ATL-D ¼ 30.5  1.8, ATL-R ¼ 30.2  3.3,
and ATL-D/R ¼ 29.3  4.5 vs IR ¼ 45.2  2.1 mm Hg, P<.001) and lower mean airway pressures versus is-
chemia–reperfusion (ATL-D¼ 9.1 0.8, ATL-R ¼ 9.1 2.6, and ATL-D/R¼ 9.6 1.3 vs IR¼ 21.1 mm Hg,
P<.001). Likewise, ATL-1223–treated groups had significantly lower lung wet/dry weight, proinflammatory
cytokine expression, and lung injury scores by histology compared with ischemia–reperfusion. All parameters
of lung function and injury in ATL-1223–treated groups were similar to sham (all P>.05).
Conclusions: Pretreatment of donor lungs with ATL-1223 was as efficacious as other treatment strategies in
protecting against ischemia–reperfusion injury. If necessary, supplemental treatment of recipients with ATL-
1223may provide additional protection. These results support the development of pharmacologic A2AR agonists
for use in human clinical trials for lung transplantation. (J Thorac Cardiovasc Surg 2011;142:887-94)XDespite recent advances in lung preservation and surgical
care, outcomes after lung transplantation remain poor.
Lung ischemia–reperfusion (IR) injury after transplantation
continues to be a common and significant cause ofmorbidity
and mortality in the early postoperative period, occurring in
20% to 35% of cases.1-3 This condition, characterized by
markedly elevated oxygen alveolar-arterial gradients, se-
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Tpulmonary vascular resistance, and decreased airway com-
pliance,4,5 has been associated with approximately 30%
of early deaths after lung transplantation in the current
surgical era and often results in increased resource use
with prolonged mechanical ventilation and longer hospital
stays.1,3 Furthermore, the presence of IR injury has been
shown to have long-term effects on the transplanted lung
by increasing the risk of chronic graft rejection (bronchioli-
tis obliterans).6
Adenosine serves as a retaliatory metabolite in posttrans-
plantation IR injury by exerting potent anti-inflammatory
effects.7 This endogenous compound mediates its influence
through interaction with 4 different G protein-coupled
adenosine receptors: A1R, A2AR, A2BR, and A3R.
8 Each
of these receptor subtypes is expressed within the lung,9
and the effects of adenosine receptor signaling are classi-
cally propagated through the cAMP and phospholipase C
second messenger pathways. Activation of the adenosine
A2A receptor (A2AR) is well known to exert anti-
inflammatory effects, and the A2AR is predominantly ex-
pressed on inflammatory cells including neutrophils, mast
cells, macrophages, monocytes, and T cells. Specifically,
A2AR activation prevents leukocyte adhesion to endothelialrdiovascular Surgery c Volume 142, Number 4 887
Abbreviations and Acronyms
A2AR ¼ adenosine A2A receptor
BAL ¼ bronchoalveolar lavage
IL ¼ interleukin
IR ¼ ischemia–reperfusion
PA ¼ pulmonary artery
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Xcells and inhibits the release of toxic oxygen products dur-
ing the respiratory burst.10 Our laboratory has previously
demonstrated that pharmacologic activation of the A2AR
significantly attenuates lung IR injury in several different
in vivo and ex vivo small and large animal models.11-15
However, the effect of different treatment strategies in
a preclinical lung transplantation model remains unknown.
The purpose of this study was to compare the efficacy of
3 different strategies for administration of A2AR agonist in
a clinically relevant porcine lung transplantation model:
pretreatment of donor lungs, treatment of the recipient after
transplantation, and a combination of both treatments. Fur-
ther defining the optimal treatment strategy for A2AR ago-
nist administration in a preclinical transplant model
remains crucial to providing a solid foundation for the de-
velopment of pharmacologic compounds, such as A2AR ag-
onists, for use in future human clinical trials to prevent IR
injury after transplantation.MATERIALS AND METHODS
Animal Care
The University of Virginia Animal Care and Use Committee reviewed
and approved all aspects of this experimental protocol before the com-
mencement of this study. Humane animal care was observed in accordance
with the ‘‘Guide for Care and Use of Laboratory Animals’’ (National Insti-
tutes of Health publication no. 85-23, revised 1985).
Study Groups
Mature domestic swine of both sexes (18–40 kg) were randomly distrib-
uted among 5 different study groups (n¼ 6/group) that were defined on the
basis of treatment with or without ATL-1223 (Dogwood Pharmaceuticals,
Charlottesville, Va), a selective A2AR agonist. The sham group underwent
a left thoracotomy alone with no ATL-1223 treatment and served as the
negative control. The IR group underwent lung procurement and transplan-
tation with no ATL-1223 treatment and served as the positive control. The
ATL-D group received a single ATL-1223 bolus treatment to the donor an-
imals (1.5 mg/kg) before transplantation. The ATL-R group received a con-
tinuous infusion of ATL-1223 (3.0 ng/kg/min) during the entire 4-hour
reperfusion period after transplantation. The ATL-D/R group received
a combination of both ATL-1223 treatment strategies. The dose of ATL-
1223 during reperfusion was based on preliminary experiments with this
drug and on previous studies from our laboratory.11,14 The ATL-1223 infu-
sion was started 10 minutes before the initiation of reperfusion to ensure
adequate circulation of the agonist to the transplanted lung on reperfusion.
The ATL-1223 bolus was administered by intravenous injection 20minutes
before donor lung ischemia and procurement, a time chosen on the basis of
an estimated 20-minute half-life for ATL-1223 in serum because of its sim-
ilarity to other compounds with known pharmacokinetics in the same888 The Journal of Thoracic and Cardiovascular Surgchemical class (Dogwood Pharmaceuticals, data not shown). After trans-
plantation or sham surgery, lungs of all animals were perfused in vivo
for a continuous 4-hour period, after which parameters of lung function
and injury were assessed as described below.
Porcine Left Lung Donor Procedure
Donor left-lung procurement was performed using a standard operative
technique as previously described.14,16 Briefly, animals were anesthetized
with ketamine (50 mg/kg) and xylazine (5 mg/kg) and ventilated with
room air using a volume-control ventilator (Harvard Apparatus, Boston,
Mass). After intubation, anesthesia was maintained with 2% isoflurane
and 100% fraction of inspired oxygen, and the lungs were ventilated to
a tidal volume of 8.0 mL/kg with a respiratory rate of 18 to 20 breaths/
min and a positive end-expiratory pressure of 5.0 cm H2O. Each animal
was placed in the supine position and prepped and draped in a standard sur-
gical fashion. Systemic anticoagulation was achieved using an intravenous
bolus dose of heparin sodium (200 U/kg). Donor animals underwent a me-
dian sternotomy and pericardiotomy to expose the heart, great vessels, and
both lungs. After dissection of the aortopulmonary window, the main pul-
monary artery (PA) was cannulated with a cardioplegia cannula (Sarns,
Ann Arbor, Mich) approximately 1.5 cm distal to the pulmonary valve.
Prostaglandin E1 (10 mg/kg) was injected directly into the main PA and al-
lowed to circulate for 10 minutes before crossclamping. The superior vena
cava was then excluded, the left atrial appendage was incised, and the in-
ferior vena cava was divided to ensure appropriate lung isolation and drain-
age. Antegrade flushing of both lungs was then performedwith 1.5 L of 4C
Perfadex (Vitrolife Inc, Denver, Colo), a commercially available preserva-
tion solution widely used during human lung transplantation, through the
PA cannula from a height of 30 cm while both lungs were cooled using
4C saline slush. On completion of the flush, both lungs were inflated
with 100% oxygen to tidal volume, and the trachea was clamped. The heart
and both lungs were then explanted en bloc.
After explantation, the left and right lungs were separated and the heart
was excised, ensuring the presence of a generous left atrial cuff. The donor
lung was then retrograde perfused with an additional 500 mL 4C Perfadex
through each pulmonary vein to remove any remaining small clots from the
pulmonary vasculature. The donor lung was then doubly wrapped in a ster-
ile bag and stored in cold Perfadex at 4C for 6 hours before transplanta-
tion. This cold ischemic time has been shown to result in significant and
reproducible lung injury in the porcine model.16
Porcine Left Lung Recipient Transplantation
Size-matched recipient swine underwent identical preoperative prepara-
tion as donor animals, including induction and maintenance anesthesia,
neck dissection with arterial and venous line placement, and PA catheter
positioning. Each animal was placed in a right, lateral decubitus position
and shaved, prepped, and draped in a normal sterile fashion. A left thora-
cotomy was then performed, and the left lung hilum was visualized. The
hemiazygos vein was first suture ligated and divided, and the peribronchial
lymph nodes were dissected free from all vascular and bronchial structures.
The left hilum was then carefully exposed to obtain circumferential dissec-
tion of the main, left, and right pulmonary arteries, the right main bronchus,
and the left superior and inferior pulmonary veins. A vessel loop was then
passed around the right PA immediately distal to its bifurcation from the
main PA for later occlusion. The left inferior pulmonary ligament was
then divided, and the pleura was dissected to the level of the hilum. A
left pneumonectomy was performed after clamping of the left PA just distal
to the bifurcation with subsequent suture ligation and division of the left
and right pulmonary veins and division of the left main stem bronchus.
Care was taken to ensure adequate PA and bronchial cuffs before their di-
vision to allow for tension-free anastomoses during transplantation. The
explanted lung was then discarded.
A left lung transplant of the preserved donor lung was performed after 6
hours of cold ischemia. Immediately after removing the donor lung fromery c October 2011
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Xice, the donor left main stem bronchus was anastomosed to the recipient left
main stem bronchial cuff using 4-0 Prolene suture (Ethicon, Inc, Somer-
ville, NJ) in a continuous fashion. The bronchial anastomosis was then
tested to ensure the absence of a leak before anastomosis of the left pulmo-
nary arteries with continuous 5-0 Prolene suture. A generous portion of the
left atrial appendage was then isolated with a side-biting vascular clamp
and incised to provide an appropriate cuff for subsequent anastomosis to
the donor pulmonary veins. Before completion of the left pulmonary
vein anastomosis, the left PA was unclamped to establish reperfusion of
the lung and to ensure adequate venting and drainage of the pulmonary vas-
culature. The pulmonary vein–left atrial anastomosis was then tied down
securely, and adequate hemostasis was confirmed. The left thoracotomy
was then closed using interrupted, figure-of-8, 0 Vicryl sutures (Ethicon,
Inc), and the skin was reapproximated with staples.
Lung Physiology
All lungs underwent an initial 3.5 hours of reperfusion whereon the right
main PA was occluded for an additional 30 minutes to assess pulmonary
function of the isolated left lung at the 4-hour reperfusion time point. Dur-
ing the entire reperfusion period, hourly arterial blood gas measurements
were obtained in addition to assessment of physiologic status through mea-
surement of mean arterial pressure and heart rate. Ventilator settings were
adjusted as needed to maintain normal pH, PCO2, and PO2 during the initial
3.5 hours of reperfusion; however, no ventilation changes were made dur-
ing the final 30-minute reperfusion period of the isolated graft. On isolation
of the donor lung, baseline pulmonary function was assessed through mea-
surement of mean airway pressure, tidal volume, peak inspiratory pressure,
and minute volume using a pressure ventilator (Servo ventilator 900C,
Siemens-Elema, Solna, Sweden), and the PA catheter was used to obtain
measurements of PA pressure, wedge pressure, cardiac output, cardiac in-
dex, pulmonary vascular resistance, and systemic vascular resistance. On
conclusion of the 4-hour reperfusion period, additional assessment of the
recipient animal and the transplanted donor lung was performed to obtain
final arterial blood gas, pulmonary function, and PA catheter measurements
before explantation of the transplanted lung.
Bronchoalveolar Lavage and Cytokine
Measurements
Bronchoalveolar lavage (BAL) of the upper lobe of the left lung in all
groups was immediately performed after explantation using 40 mL of nor-
mal saline and repeated twice. BAL samples underwent centrifugation at
10,000 rpm at 4C for 20 minutes to remove cells and debris, and the su-
pernatant was collected and stored frozen at80C. Quantification of cyto-
kine levels in BAL fluid was assessed using a commercially available
porcine cytokine multiplex immunoassay kit (Aushon BioSystems, Inc,
Billerica, Mass) according to the manufacturer’s protocol. All BAL sam-
ples were tested in duplicate and averaged. Cytokine concentrations are ex-
pressed in picograms per milliliter.
Lung Wet/Dry Weight
Fresh lung tissue samples obtained from the lower lobe were blotted to
remove excess blood and weighed before placement in a 52C vacuum
oven for 48 to 72 hours. The samples were weighed daily until the weight
was stable. The wet-to-dry weight ratio was used to assess pulmonary
edema, wherein high wet/dry weight is indicative of pulmonary edema.
Histopathology and Lung Injury Severity Score
The lower lobe was fixed in 4% paraformaldehyde, via tracheal infla-
tion under constant 25 cm pressure, for 24 hours with subsequent paraffin
embedding and hematoxylin–eosin staining. The portion of the lower lobe
used to collect tissue for wet/dry weight was excluded from fixation via li-
gation of the airway supplying that portion of the lobe. Lung sections were
blindly assessed by 2 separate lung pathologists and graded according toThe Journal of Thoracic and Cathe degree of interstitial infiltration, total neutrophil counts per high power
field, and extent of alveolar edema. A score on a scale of 0 to 3 was assigned
for each section using previously reported criteria: neutrophils per high-
powered field (score: 0 ¼<5 cells, 1 ¼ 6–10 cells, 2 ¼ 11–20 cells,
3 ¼>20 cells), interstitial infiltration (score: 0 ¼ none, 1 ¼ minimal,
2 ¼ moderate, 3 ¼ severe), alveolar edema (score: 0 ¼<5%, 1 ¼ 6%–
25%, 2 ¼ 26%–50%, 3 ¼>50%).14
Statistical Analysis
All experimental methodology was designed to test the null hypothesis
that no significant differences in the degree of IR injury after lung trans-
plantation would be observed despite A2AR agonist treatment strategy. In-
dependent, pairwise group comparisons of mean differences in measured
results were performed using analysis of variance. To provide a conserva-
tive estimate of these differences, all probability estimates were adjusted
for the potential influence of multiple group comparisons using a post
hoc Bonferroni correction. Experimental results are reported as mean 
standard error of the mean. All calculated test statistics were used to gen-
erate reported P values. All P values are 2-tailed.RESULTS
Lung Function
Lung function after transplantation was significantly im-
proved in all groups that received A2AR agonist treatment
(Figure 1). Blood oxygenation was significantly higher
among ATL-D, ATL-R, and ATL-D/R groups compared
with IR control (392.0  52.5, 428.9  25.5, 509.4 
25.1 vs 77.2  17.0 mm Hg, respectively, P<.001). Like-
wise, all ATL-1223–treated groups had significantly lower
PA pressures (ATL-D ¼ 30.5  1.8, ATL-R ¼ 30.2  3.3,
ATL-D/R ¼ 29.3  4.5 vs IR ¼ 45.2  2.1 mm Hg,
P < .001) and lower mean airway pressures compared
with IR control (ATL-D ¼ 9.1  0.8, ATL-R ¼ 9.1  2.6,
ATL-D/R¼ 9.6 1.3 vs IR¼ 21.1 mmHg, P<.001). How-
ever, no significant differences were observed for these
measurements either between the ATL-1223 treatment
groups or between each treatment group and the sham group
(allP>.05). No significant differences in median total anas-
tomosis (graft implant warm ischemia) time existed be-
tween experimental groups (IR control ¼ 37.5 minutes,
ATL-D ¼ 29.5 minutes, ATL-R: 32.0 minutes, ATL D/
R¼ 26.5 minutes, all P>.05). In addition, no significant dif-
ferences among all groups were observed for mean arterial
pressure, cardiac output, cardiac index, systemic vascular
resistance, or pulmonary capillary wedge pressure (data
not shown).Pulmonary Edema
The degree of pulmonary edema was determined by lung
wet/dry weight ratios, which was significantly reduced in all
ATL-1223 treatment groups (Figure 2). As expected, the IR
group (7.7  0.4) had significantly increased wet/dry
weight compared with sham (5.0  0.2) (P< .05). ATL-
1223–treated lungs had significantly lower wet/dry weight
compared with IR control animals (ATL-D ¼ 4.8  0.3,
ATL-R ¼ 5.2  0.3, ATL-D/R ¼ 4.9  0.2 vs IR ¼ 7.7 rdiovascular Surgery c Volume 142, Number 4 889
FIGURE 1. Lung physiology after 4 hours of reperfusion. A, Mean blood
oxygenation (mm Hg) as assessed by measured PO2 on arterial blood gas
analysis. B, Mean PA pressure (mm Hg). C, Mean airway pressure (mm
Hg). Groups: thoracotomy alone (sham), left lung transplant (IR), ATL-
1223 bolus pretreatment to donor lung (ATL-D), ATL-1223 infusion during
reperfusion of donor lung (ATL-R), and a combination of ATL-1223 pre-
treatment and infusion during reperfusion (ATL-D/R). *P< .05 vs all.
IR, Ischemia–reperfusion.
FIGURE 2. Mean lung wet/dry weight ratios after 4 hours of reperfusion.
Groups: thoracotomy alone (sham), left lung transplant (IR), ATL-1223 bo-
lus pretreatment to donor lung (ATL-D), ATL-1223 infusion during reper-
fusion of donor lung (ATL-R), and a combination of ATL-1223
pretreatment and infusion during reperfusion (ATL-D/R). *P<.05 vs all.
IR, Ischemia–reperfusion.
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X0.4, all P < .05). No significant differences in wet/dry
weight existed between the ATL-1223 treatment groups or
the sham group (all P>.05).Proinflammatory Cytokine Expression
The effect of various ATL-1223 treatment strategies on
the expression of proinflammatory cytokines in BAL fluid
was assessed at the end of reperfusion (Table 1). As ex-
pected, the IR group had significantly increased expression
of cytokines compared with sham. Pretreatment with ATL-890 The Journal of Thoracic and Cardiovascular Surg1223 (ATL-D group), treatment of the recipient (ATL-R
group), or combined treatment (ATL-D/R group) all re-
sulted in significantly reduced expression of interleukin
(IL)-1b, IL-8, IL-10, interferon-g, and tumor necrosis fac-
tor-a compared with IR control (Table 1). The expression
of each of these cytokines in all ATL-1223–treated groups
was similar to that for sham animals (all P>.05).Gross and Histologic Evidence of Lung Injury
Overall, ATL-1223 treatment resulted in improved gross
and histologic appearance (Figure 3) and decreased mean
histologic injury scores (Table 2) compared with IR con-
trols. Total lung injury scores for all 3 ATL-1223 treatment
groups were significantly lower than IR control (ATL-
D ¼ 1.50  0.22, ATL-R ¼ 1.52  0.39, ATL-D/
R ¼ 1.67  0.21 vs IR control ¼ 4.83  0.31, all
P<.05). In addition, neutrophil infiltration, edema, and in-
terstitial infiltrates were all elevated in the IR group versus
sham and were significantly reduced in each of the ATL-
1223–treated groups versus IR (Table 2). Lung injury scores
for the ATL-1223 treatment groups were similar to those of
sham animals (1.00  0.45). On examination of each score
category, the quantity of infiltrating neutrophils among IR
controls proved to be the largest determinant of overall
score differences when compared with ATL-1223 treatment
and sham groups.DISCUSSION
The present study used a preclinical porcine lung trans-
plantation model to investigate the most efficacious and
practical treatment strategy for the attenuation of acute
lung IR injury through pharmacologic activation of A2AR.
The results demonstrate that a pretreatment strategy, using
a single bolus dose of ATL-1223 administered to the donor
before procurement, is efficacious and significantlyery c October 2011
TABLE 1. Cytokine levels in bronchoalveolar lavage fluid
Sham IR ATL-D ATL-R ATL-D/R
IL-1b (pg/mL) 28.6  1.2* 265.1  43.7 31.8  7.0* 31.1  2.7* 25.0  2.1*
IL-8 (pg/mL) 51.3  16.7* 222.4  41.4 91.2  26.9* 60.9  24.3* 76.7  33.9*
IL-10 (pg/mL) 2.7  0.8* 63.1  13.1 13.3  9.9* 2.3  0.2* 3.7  1.1*
INF-g (pg/mL) 5.1  0.7* 248.2  87.0 13.2  6.2* 7.3  2.4* 5.3  2.1*
TNF-a (pg/mL) 2.5  0.6* 25.9  4.6 2.8  0.6* 2.2  0.4* 2.6  0.6*
*P<.05 vs IR. Results reported as mean  standard error.
LaPar et al Cardiothoracic Transplantationattenuates posttransplantation IR injury. The preserved pul-
monary condition afforded by a pretreatment strategy was
associated with improved lung physiology, reduced pulmo-
nary edema, decreased expression of proinflammatory cyto-
kines, decreased neutrophil infiltration, and conserved lung
histology. More important, pretreatment of donor lungs
with ATL-1223 provided a similar level of protection
from IR injury compared with either ATL-1223 treatment
of the recipient alone or a combined ATL-1223 treatment
strategy. In addition, the degree of protection after pretreat-
ment of donor lungs resulted in parameters of lung function
and injury that were not significantly different from the
sham group. These results not only corroborate data from
previous studies using small animal models of lung IR in-
jury but, more important, also provide a solid foundation
from which to advance the development of pharmacologic
A2AR agonists for use in human clinical trials.
The pharmacologic pretreatment strategy used in this
study mimics the beneficial effects of adenosine modulation
after ischemic preconditioning in other experimental re-
ports.17-19 During ischemic preconditioning, brief periods
of ischemia and hypoxia are associated with accumulating
levels of extracellular adenosine. Elevated levels of
adenosine have been demonstrated to confer benefitsFIGURE 3. Representative gross (top) and histologic (bottom, hematoxylin–eo
thoracotomy alone (sham), left lung transplant (IR), ATL-1223 bolus pretreatme
lung (ATL-R), and a combination of ATL-1223 pretreatment and infusion duri
The Journal of Thoracic and Cabefore prolonged ischemia within several different organ
systems, including the liver, lung, heart, and kidney.17,18,20
Although the precise mechanisms underlying the benefits
of elevated adenosine during the preischemic state are not
well understood, adenosine receptor activation appears
crucial. With respect to lung IR injury, we have previously
demonstrated the protective benefits of pharmacologic
A2AR activation as pretreatment in an ex vivo blood-
perfused rabbit lung model,11 results that were confirmed
in the present study. In a related study by Yildiz and col-
leagues,19 similar benefits of adenosine pretreatment were
demonstrated in an isolated, buffer perfused rat-lung model
of IR injury. These 2 studies were limited, however, by the
use of small animal, ex vivo models of lung inflammation
and do not represent true transplant models. Thus, the use
of an in vivo, clinically translatable animal model of lung
transplantation was an important advantage in the present
study.
The molecular and cellular mechanisms involved in lung
IR injury and the role of adenosinemodulation have been in-
creasingly documented and are currently a source of contin-
ued investigation; however, the mechanisms involved in the
abrogation of lung IR injury after an adenosine pretreatment
strategy remain unknown. Accumulated data havesin sections, 403) appearance of lungs after 4 hours of reperfusion. Groups:
nt to donor lung (ATL-D), ATL-1223 infusion during reperfusion of donor
ng reperfusion (ATL-D/R). IR, Ischemia–reperfusion.
rdiovascular Surgery c Volume 142, Number 4 891
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TABLE 2. Lung injury severity scores by histology
Neutrophils
Alveolar
edema
Interstitial
infiltrate Total score
Sham 0.67  0.33* 0.00  0.00* 0.33  0.21* 1.00  0.45*
IR 2.17  0.17 1.50  0.22 1.17  0.31 4.83  0.31
ATL-D 0.67  0.21* 0.50  0.22* 0.36  0.29* 1.50  0.22*
ATL-R 1.17  0.17* 0.00  0.00* 0.67  0.21* 1.52  0.39*
ATL-D/R 1.00  0.26* 0.00  0.00* 0.67  0.21* 1.67  0.21*
See ‘‘Materials and Methods’’ for scoring criteria. *P<.05 versus IR. Results re-
ported as mean  standard error.
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Xdemonstrated that alveolar macrophages and infiltrating
neutrophils and CD4þ T lymphocytes play an important
role in acute IR injury.15,21-23 In addition, activation of
A2AR, which is predominantly expressed on inflammatory
cells including neutrophils, mast cells, macrophages,
monocytes, and T cells, has been shown to attenuate lung
injury through a variety of mechanistic pathways involving
decreased release of tumor necrosis factor-a and other
proinflammatory cytokines, downregulation of adhesion
molecules (P-selectin, intercellular adhesion molecule-1,
and vascular cell adhesion molecule-1), and blocking of
neutrophil activation and infiltration.10-12,14,15,21,24 In the
current study, ATL-1223 treatment resulted in significantly
decreased proinflammatory cytokine expression when
administered either before ischemia or during reperfusion.
In addition, neutrophil counts were similarly decreased after
administration ofATL-1223 regardless of treatment strategy.
Although the specific mechanisms underlying the improve-
ment in lung function after pretreatment of donor lungs
withATL-1223was not an objective of this study, indirect ev-
idence of decreased neutrophil activation and reduced
cytokine and chemokine expression suggests that pretreat-
ment of the donor lung serves to ‘‘deactivate’’ immune cells
in the donor lung to exert a protective effect on reperfusion.
Deactivation of cells, such as alveolarmacrophages andmar-
ginated neutrophils, before the ischemic insult may serve to
inhibit the characteristic respiratory burst that typically
occurs on reperfusion.
Several important considerations related to the experi-
mental methodology of this study deserve further discus-
sion. First, the total anastomosis time, which represents
the amount of ‘‘warm’’ ischemic time that the donor lung
experienced before reperfusion, was consistent and short
(25–30 minutes) in our model. Prolonged warm ischemic
time has a strong association with worse lung injury after
transplantation.25,26 Thus the potential for this
confounding influence was reduced between study groups.
Second, all experimental groups had similar mean arterial
pressures and cardiac function during the reperfusion
period, which reduces the potential impact of variable
hemodynamics between groups on lung injury outcomes.
Third, a total of 38 transplants were performed in this
study. Of the 8 transplants that were excluded, 3 were892 The Journal of Thoracic and Cardiovascular Surgexcluded because of unexpected intraoperative death from
technical complications, and 5 were excluded because of
poor recipient lung condition from either active or prior
pneumonia. The relatively short estimated half-life of
ATL-1223 provided the rationale in our study for adminis-
tering ATL-1223 to the pretreatment group 20 minutes be-
fore ischemia and to the recipient as a constant infusion
during the 4-hour reperfusion period. However, in view of
the efficacy of a single pretreatment bolus, we would specu-
late that a single bolus treatment of ATL-1223 on reperfu-
sion might be as effective as a constant infusion. Finally,
an established side effect of adenosine A2AR agonists,
such asATL-1223, is vasodilation and systemic hypotension
after administration of relatively high doses of these com-
pounds. Thus, dosing strategies used in this study were de-
signed to allow for the provision of the lowest, yet still
efficacious dose of ATL-1223 to both donor and recipient
animals without any significant systemic hypotension.
No clinical therapies are currently available that specifi-
cally target IR injury; however, the specific targeting of
A2AR may offer therapeutic strategies in this regard. Thus,
the present results have significant clinical implications.
The fact that a single bolus, pretreatment of ATL-1223 be-
fore donor lung procurement results in significant protection
from acute lung IR injury, and that this level of protection is
similar to that achieved after treatment during reperfusion,
provides evidence for a simple and efficacious treatment
strategy to prevent IR injury. Underscoring the significance
of these results is the observation that the pretreatment strat-
egy resulted in pulmonary function comparable to that of
sham animals. Such a pretreatment strategy could be easily
implemented into current lung transplantation procurement
protocols similar to that currently used for the administra-
tion of pre-procurement prostaglandin. Although the
combined treatment ofATL-1223 in our study did not signif-
icantly enhance protection above the single treatments, it is
still possible that a combined treatment strategy, involving
treatment of ATL-1223 before ischemia with supplemental
treatment during reperfusion, could confer additional pro-
tection in some cases where unanticipated inflammation oc-
curs after transplantation. Such an approach may prove
especially beneficial for marginal donor lungs or for donor
lungs that are subjected to prolonged ischemic times. In ad-
dition to benefiting the patient acutely, preventing lung IR
injury through pharmacologic A2AR activation would likely
provide long-term benefits by reducing the incidence of
bronchiolitis obliterans. A pretreatment strategy for A2AR
activation may also prove beneficial to reduce the incidence
of IR injury after the transplantation of other solid organs,
such as liver, kidney, small intestine, and pancreas. Thus,
these results have significant and broad implications for
the future of human organ transplantation.
The reported results yield potential areas for future inves-
tigation. The underlying mechanisms involved in protectionery c October 2011
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warranted. In addition, further study to more clearly define
the length of ischemic time that can be tolerated after pre-
treatment of donor lungs with ATL-1223 will be required
to define the full potential of this treatment strategy. It is
possible that treatment of donor lungs with ATL-1223
may allow for longer ischemic times than are currently ac-
ceptable after lung procurement, which ultimately may
serve to help redefine transplantation protocols in the not-
too-distant future.
CONCLUSIONS
Pretreatment of donor lungs with a bolus dose of A2AR
agonist proves efficacious and confers a similar level of pro-
tection from acute IR injury as other treatment strategies.
This pretreatment strategy could be easily implemented
into current, routine organ procurement protocols. A com-
bined treatment strategy with supplemental A2AR agonist
administration to the recipient during reperfusion may
provide additional attenuation of inflammation after trans-
plantation. These results support the development of phar-
macologic A2AR agonists for use in human clinical trials
to prevent acute graft failure after transplantation.
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Dr Patrick M. McCarthy (Chicago, Ill). That was a very clear
presentation. Is there work ongoing in other organs? The concern
would be about treating the lung donor if the effects on the other
organs are unknown.
Dr LaPar. That is a very pertinent question. An extensive
amount of work has been done with similar adenosine compounds
in other organ systems, such as the kidney and the liver, and these
investigations have demonstrated a significant benefit to using
these agonists. To my knowledge, the use of the ATL-1223 com-
pound as donor treatment in other organ systems has not been re-
ported. However, on the basis of this study, we are now beginning
experimental work with our other transplant colleagues to investi-
gate the potential benefits of such treatment in other organ
systems.rdiovascular Surgery c Volume 142, Number 4 893
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XDr J. William Gaynor (Philadelphia, Pa). Was any immuno-
suppression used in this model?
Dr LaPar. No.
Dr Gaynor. Are there any drug interactions of this agent with
the commonly used immunosuppressive agents? If you give
some other anti-inflammatory drug, such as a bolus of steroids,
will you see the same marked effect?
Dr LaPar. To my knowledge, there are no documented interac-
tions between immunosuppressive drugs such as steroids and some
of the other A2A agonists that we have used in the past, including
ATL-146e or ATL-313. As for ATL-1223, the pharmacokinetics
and drug interaction profiles are currently being investigated.
However, on the basis of what we know of the other compounds,
I would not anticipate any unforeseen negative interactions with
concomitant immunosuppressive therapy.
Dr Michael E. Jessen (Dallas, Tex). This is a very interesting
study. As you are moving toward clinical trials, I am concerned
that your model does not quite model what happens in the clinical
arena. Most donors have undergone some form of trauma or some894 The Journal of Thoracic and Cardiovascular Surgother event before organ procurement, which could incite the in-
flammatory response. Any time you are giving even a preoperative
dose of the drug, there actually may already be an inflammatory
response started. It sounded as though your protocol does not favor
brain death, either, the process of which also incites a lot of inflam-
matory cytokine response. Would you be wiser to look at some of
those scenarios before you take this to the clinical arena?
Dr LaPar. Thank you very much, Dr Jessen, for that question.
You bring up an important point that a donor setting after multiple
trauma or brain injury may be different from what we modeled in
the laboratory in this study. In these settings, it is widely known
that a profound inflammatory response is likely and that adenosine,
in general, has profound anti-inflammatory effects. Thus I believe
that even in these settings, provision of an agonist such as ATL-
1223 to the donor is going to confer a greater level of protection
than what can be achieved without it. I further believe that for
certain patients supplemental treatment to the recipient could be
beneficial to provide additional protection after establishing
reperfusion.ery c October 2011
